Bone marrow-derived heparan sulfate potentiates the osteogenic activity of bone morphogenetic protein-2 (BMP-2)

Bone

Volumn 50, Issue 4, 2012, Pages 954-964

  Bramono, Diah S ^a   Murali, Sadasivam ^a   Rai, Bina ^a   Ling, Ling ^a   Poh, Wei Theng ^a   Lim, Zophia Xuehui ^a   Stein, Gary S ^b   Nurcombe, Victor ^a,c   van Wijnen, Andre J ^b   Cool, Simon M ^a,c  

^a INSTITUTE OF MEDICAL BIOLOGY   (Singapore)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Bone growth factor; Bone forming; Glycosaminoglycan; Heparan sulfate; Heparin

Indexed keywords

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; HEPARAN SULFATE; HEPARIN; NOGGIN; OSTEOCALCIN;

ARTICLE; BONE DEVELOPMENT; BONE MARROW; BONE REMODELING; CELL SURFACE; CONTROLLED STUDY; COW; DRUG BIOAVAILABILITY; DRUG ISOLATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG PURIFICATION; ENZYME ACTIVITY; HALF LIFE TIME; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; LONG TERM CARE; LUNG; MYOBLAST; OSSIFICATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; STROMA CELL; SUPPLEMENTATION; SWINE;

ANIMALS; BIOLOGICAL AVAILABILITY; BONE MARROW CELLS; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE I; CARRIER PROTEINS; CATTLE; CELL DIFFERENTIATION; CELL LINE; CHORISTOMA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, ION EXCHANGE; CULTURE MEDIA, CONDITIONED; DISACCHARIDES; DRUG SYNERGISM; FEMALE; HEPARIN; HEPARITIN SULFATE; HUMANS; MICE; OSTEOGENESIS; PROTEIN BINDING; PROTEIN STABILITY; RATS; RATS, SPRAGUE-DAWLEY; STROMAL CELLS; SUS SCROFA;

EID: 84858070575     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.12.013     Document Type: Article

References (66)

1. Bishop G.B., Einhorn T.A. Current and future clinical applications of bone morphogenetic proteins in orthopaedic trauma surgery. Int Orthop 2007, 31:721-727.
2. Dinopoulos H., Giannoudis P.V. The use of bone morphogenetic proteins (BMPs) in long-bone non-unions. Curr Orthop 2007, 21:268-279.
3. Gautschi O.P., Frey S.P., Zellweger R. Bone morphogenetic proteins in clinical applications. ANZ J Surg 2007, 77:626-631.
4. Garrison K.R., Donell S., Ryder J., Shemilt I., Mugford M., Harvey I., et al. Clinical effectiveness and cost-effectiveness of bone morphogenetic proteins in the non-healing of fractures and spinal fusion: a systematic review. Health Technol Assess 2007, 11.
5. Chung Y.I., Ahn K.M., Jeon S.H., Lee S.Y., Lee J.H., Tae G. Enhanced bone regeneration with BMP-2 loaded functional nanoparticle-hydrogel complex. J Control Release 2007, 121:91-99.
6. Fu Y.C., Nie H., Ho M.L., Wang C.K., Wang C.H. Optimized bone regeneration based on sustained release from three-dimensional fibrous PLGA/HAp composite scaffolds loaded with BMP-2. Biotechnol Bioeng 2008, 99:996-1006.
7. Jeon O., Song S.J., Yang H.S., Bhang S.H., Kang S.W., Sung M.A., et al. Long-term delivery enhances in vivo osteogenic efficacy of bone morphogenetic protein-2 compared to short-term delivery. Biochem Biophys Res Commun 2008, 369:774-780.
8. Karageorgiou V., Tomkins M., Fajardo R., Meinel L., Snyder B., Wade K., et al. Porous silk fibroin 3-D scaffolds for delivery of bone morphogenetic protein-2 in vitro and in vivo. J Biomed Mater Res A 2006, 78A:324-334.
9. Takada T., Katagiri T., Ifuku M., Morimura N., Kobayashi M., Hasegawa K., et al. Sulfated polysaccharides enhance the biological activities of bone morphogenetic proteins. J Biol Chem 2003, 278:43229-43235.
10. Esko J.D., Linhardt R.J. Proteins that bind sulfated glycosaminoglycans. Essentials of glycobiology 2008, Cold Spring Harbor Laboratory Press, La Jolla, California. A. Varki, R.D. Cummings, J.D. Esko, H.H. Freeze, P. Stanley, C.R. Bertozzi, G.W. Hart, M.E. Etzler (Eds.).
11. Zhao B.H., Katagiri T., Toyoda H., Takada T., Yanai T., Fukuda T., et al. Heparin potentiates the in vivo ectopic bone formation induced by bone morphogenetic protein-2. J Biol Chem 2006, 281:23246-23253.
12. Paine-Saunders S., Viviano B.L., Economides A.N., Saunders S. Heparan sulfate proteoglycans retain Noggin at the cell surface - a potential mechanism for shaping bone morphogenetic protein gradients. J Biol Chem 2002, 277:2089-2096.
13. Arnander C., Westermark A., Veltheim R., Docherty-Skogh A.C., Hilborn J., Engstrand T. Three-dimensional technology and bone morphogenetic protein in frontal bone reconstruction. J Craniofac Surg 2006, 17:275-279.
14. Gittens S.A., Bagnall K., Matyas J.R., Lobenberg R., Uludag H. Imparting bone mineral affinity to osteogenic proteins through heparin-bisphosphonate conjugates. J Control Release 2004, 98:255-268.
15. Lin H., Zhaol Y., Sun W.J., Chen B., Zhang J., Zhao W.X., et al. The effect of crosslinking heparin to demineralized bone matrix on mechanical strength and specific binding to human bone morphogenetic protein-2. Biomaterials 2008, 29:1189-1197.
16. Atha D.H., Stephens A.W., Rosenberg R.D. Evaluation of critical groups required for the binding of heparin to antithrombin. Proc Natl Acad Sci USA 1984, 81:1030-1034.
17. Park S.H., Silva M., Bahk W.J., McKellop H., Lieberman J.R. Effect of repeated irrigation and debridement on fracture healing in an animal model. J Orthop Res 2002, 20:1197-1204.
18. Barbour L.A., Kick S.D., Steiner J.F., LoVerde M.E., Heddleston L.N., Lear J.L., et al. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 1994, 170:862-869.
19. Muir J.M., Andrew M., Hirsh J., Weitz J.I., Young E., Deschamps P., et al. Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. Blood 1996, 88:1314-1320.
20. Chowdhury M.H., Hamada C., Dempster D.W. Effects of heparin on osteoclast activity. J Bone Miner Res 1992, 7:771-777.
21. Goldhaber P. Heparin enhancement of factors stimulating bone resorption in tissue culture. Science 1965, 147:407-408.
22. Irie A., Takami M., Kubo H., Sekino-Suzuki N., Kasahara K., Sanai Y. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. Bone 2007, 41:165-174.
23. Esko J.D., Selleck S.B. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem 2002, 71:435-471.
24. Gupta P., McCarthy J.B., Verfaillie C.M. Stromal fibroblast heparan sulfate is required for cytokine-mediated ex vivo maintenance of human long-term culture-initiating cells. Blood 1996, 87:3229-3236.
25. Jackson R.A., Murali S., Van Wijnen A.J., Stein G.S., Nurcombe V., Cool S.M. Heparan sulfate regulates the anabolic activity of MC3T3-E1 preosteoblast cells by induction of Runx2. J Cell Physiol 2007, 210:38-50.
26. Jackson R.A., McDonald M.M., Nurcombe V., Little D.G., Cool S.M. The use of heparan sulfate to augment fracture repair in a rat fracture model. J Orthop Res 2006, 24:636-644.
27. Bramono D., Rider D., Murali S., Nurcombe V., Cool S. The effect of human bone marrow stroma-derived heparan sulfate on the ex vivo expansion of human cord blood hematopoietic stem cells. Pharm Res 2011, 28:1385-1394.
28. Jung Y.G., Song J.H., Shiozawa Y., Wang J.C., Wang Z., Williams B., et al. Hematopoietic stem cells regulate mesenchymal stromal cell induction into osteoblasts thereby participating in the formation of the stem cell niche. Stem Cells 2008, 26:2042-2051.
29. Lu H., McDowell L.M., Studelska D.R., Zhang L. Glycosaminoglycans in human and bovine serum: detection of twenty-four heparan sulfate and chondroitin sulfate motifs including a novel sialic acid-modified chondroitin sulfate linkage hexasaccharide. Glycobiol Insights 2010, 2:13-28.
30. Murali S., Manton K.J., Tjong V., Su X.D., Haupt L.M., Cool S.M., et al. Purification and characterization of heparan sulfate from human primary osteoblasts. J Cell Biochem 2009, 108:1132-1142.
31. Brickman Y.G., Ford M.D., Gallagher J.T., Nurcombe V., Bartlett P.F., Turnbull J.E. Structural modification of fibroblast growth factor-binding heparan sulfate at a determinative stage of neural development. J Biol Chem 1998, 273:4350-4359.
32. Murali S., Leong D.F.M., Lee J.J.L., Cool S.M., Nurcombe V. Comparative assessment of the effects of gender-specific heparan sulfates on mesenchymal stem cells. J Biol Chem 2011, 286:17755-17765.
33. Osmond R.I.W., Kett W.C., Skett S.E., Coombe D.R. Protein-heparin interactions measured by BIAcore 2000 are affected by the method of heparin immobilization. Anal Biochem 2002, 310:199-207.
34. Ng K.W., Speicher T., Dombrowski C., Helledie T., Haupt L.M., Nurcombe V., et al. Osteogenic differentiation of murine embryonic stem cells is mediated by fibroblast growth factor receptors. Stem Cells Dev 2007, 16:305-318.
35. Lidholt K., Weinke J.L., Kiser C.S., Lugemwa F.N., Bame K.J., Cheifetz S., et al. A single mutation affects both N-acetylglucosaminyltransferase and glucuronosyltransferase activities in a Chinese hamster ovary cell mutant defective in heparan sulfate biosynthesis. Proc Natl Acad Sci USA 1992, 89:2267-2271.
36. Rolny C., Spillmann D., Lindahl U., Claesson-Welsh L. Heparin amplifies platelet-derived growth factor (PDGF)-BB-induced PDGF alpha-receptor but not PDGF beta-receptor tyrosine phosphorylation in heparan sulfate-deficient cells - effects on signal transduction and biological responses. J Biol Chem 2002, 277:19315-19321.
37. Yang H.S., La W.G., Bhang S.H., Jeon J.Y., Lee J.H., Kim B.S. Heparin-conjugated fibrin as an injectable system for sustained delivery of bone morphogenetic protein-2. Tissue Eng Part A 2010, 16:1225-1233.
38. Rai B., Lin J.L., Lim Z.X.H., Guldberg R.E., Hutmacher D.W., Cool S.M. Differences between in vitro viability and differentiation and in vivo bone-forming efficacy of human mesenchymal stem cells cultured on PCL-TCP scaffolds. Biomaterials 2010, 31:7960-7970.
39. Ralis Z.A., Watkins G. Modified tetrachrome method for osteoid and defectively mineralized bone in paraffin sections. Biotech Histochem 1992, 67:339-345.
40. Karamanos N.K., Vanky P., Tzanakakis G.N., Tsegenidis T., Hjerpe A. Ion-pair high-performance liquid chromatography for determining disaccharide composition in heparin and heparan sulphate. J Chromatogr A 1997, 765:169-179.
41. Hsieh C.-Y., Hsieh H.-J., Liu H.-C., Wang D.-M., Hou L.-T. Fabrication and release behavior of a novel freeze-gelled chitosan/gamma-PGA scaffold as a carrier for rhBMP-2. Dent Mater 2006, 22:622-629.
42. Jiao X.Y., Billings P.C., O'Connell M.P., Kaplan F.S., Shore E.M., Glaser D.L. Heparan sulfate proteoglycans (HSPGs) modulate BMP2 osteogenic bioactivity in C2C12 cells. J Biol Chem 2007, 282:1080-1086.
43. Kuo W.J., Digman M.A., Lander A.D. Heparan sulfate acts as a bone morphogenetic protein coreceptor by facilitating ligand-induced receptor hetero-oligomerization. Mol Biol Cell 2010, 21:4028-4041.
44. Guimond S.E., Turnbull J.E. Fibroblast growth factor receptor signalling is dictated by specific heparan sulphate saccharides. Curr Biol 1999, 9:1343-1346.
45. Conrad H.E. Heparin-binding protein 1998, Academic Press, San Diego.
46. Gorsi B., Stringer S.E. Tinkering with heparan sulfate sulfation to steer development. Trends Cell Biol 2007, 17:173-177.
47. de Agostini A.I., Dong J.-C., Arrighi CdV, Ramus M.-A., Dentand-Quadri I., Thalmann S., et al. Human follicular fluid heparan sulfate contains abundant 3-O-sulfated chains with anticoagulant activity. J Biol Chem 2008, 283:28115-28124.
48. Shworak N.W., Kobayashi T., de Agostini A., Smits N.C. Anticoagulant heparan sulfate: to not clot-or not?. Progress in Molecular Biology and Translational Science, Vol 93: Glycosaminoglycans in Development, Health and Disease 2010, 153-178. Elsevier Academic Press Inc, San Diego.
49. Korir A.K., Lirntiaco J.F.K., Gutierrez S.M., Larive C.K. Ultraperformance ion-pair liquid chromatography coupled to electrospray time-of-flight mass spectrometry for compositional profiling and quantification of heparin and heparan sulfate. Anal Chem 2008, 80:1297-1306.
50. Carlsson P., Presto J., Spillmann D., Lindahl U., Kjellen L. Heparin/heparan sulfate biosynthesis - processive formation of N-sulfated domains. J Biol Chem 2008, 283:20008-20014.
51. Holmborn K., Ledin J., Smeds E., Eriksson I., Kusche-Gullberg M., Kjellén L. Heparan sulfate synthesized by mouse embryonic stem cells deficient in NDST1 and NDST2 is 6-O-sulfated but contains no N-sulfate groups. J Biol Chem 2004, 279:42355-42358.
52. Rabenstein D.L. Heparin and heparan sulfate: structure and function. Nat Prod Rep 2002, 19:312-331.
53. Gama C.I., Tully S.E., Sotogaku N., Clark P.M., Rawat M., Vaidehi N., et al. Sulfation patterns of glycosaminoglycans encode molecular recognition and activity. Nat Chem Biol 2006, 2:467-473.
54. Gandhi N.S., Mancera R.L. The structure of glycosaminoglycans and their interactions with proteins. Chem Biol Drug Des 2008, 72:455-482.
55. Yamada S., Onishi M., Fujinawa R., Tadokoro Y., Okabayashi K., Asashima M., et al. Structural and functional changes of sulfated glycosaminoglycans in Xenopus laevis during embryogenesis. Glycobiology 2009, 19:488-498.
56. Byers B.A., Garcia A.J. Exogenous Runx2 expression enhances in vitro osteoblastic differentiation and mineralization in primary bone marrow stromal cells. Tissue Eng 2004, 10:1623-1632.
57. Perinpanayagam H., Schneider G., Holtman K., Zaharias R., Stanford C. Altered Cbfa1 expression and biomineralization in an osteosarcoma cell line. J Orthop Res 2004, 22:404-410.
58. Byers B.A., Pavlath G.K., Murphy T.J., Karsenty G., Garcia A.J. Cell-type-dependent up-regulation of in vitro mineralization after overexpression of the osteoblast-specific transcription factor Runx2/Cbfa1. J Bone Miner Res 2002, 17:1931-1944.
59. Liu W.G., Toyosawa S., Furuichi T., Kanatani N., Yoshida C., Liu Y., et al. Overexpression of Cbfa1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures. J Cell Biol 2001, 155:157-166.
60. Bhandari M., Hirsh J., Weitz J.I., Young E., Venner T.J., Shaughnessy S.G. The effects of standard and low molecular weight heparin on bone nodule formation in vitro. Thromb Haemost 1998, 80:413-417.
61. Hausser H.J., Brenner R.E. Low doses and high doses of heparin have different effects on osteoblast-like Saos-2 cells in vitro. J Cell Biochem 2004, 91:1062-1073.
62. Arici M., Erturk H., Altun B., Usalan C., Ulusoy S., Erdem Y., et al. Bone mineral density in haemodialysis patients: a comparative study of dual-energy X-ray absorptiometry and quantitative ultrasound. Nephrol Dial Transplant 2000, 15:1847-1851.
63. Bonilla C.A., Stringham R.M., Lytle I.M. Effect of heparin on serum calcium concentrations in mice. Nature 1968, 217:1281-1282.
64. Goldsmith M.W., Parry D.J. An investigation into the mechanism of the in vitro fall in rabbit plasma calcium which follows intravenous heparin injection. Clin Chim Acta 1968, 19:429-438.
65. Rabenstein D.L., Robert J.M., Peng J. Multinuclear magnetic resonance studies of the interaction of inorganic cations with heparin. Carbohydr Res 1995, 278:239-256.
66. Viviano B.L., Paine-Saunders S., Gasiunas N., Gallagher J., Saunders S. Domain-specific modification of heparan sulfate by Qsulf1 modulates the binding of the bone morphogenetic protein antagonist noggin. J Biol Chem 2004, 279:5604-5611.